Overview

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Solifenacin Succinate
Tolterodine Tartrate